CNSYCerenomeSigning up patients
Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
Leptomeningeal Metastasis
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 24 (planned)
- Started
- Jul 2, 2025
- Main results expected
- Jul 31, 2027
- Fully finished
- Oct 2, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Maximum Tolerated Dose
Measured over: 13 months
Dose Distribution of 186RNL
Measured over: 13 months
Safety and tolerability of multiple dose treatment
Measured over: 13 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07098806 · record last updated 2026-11-05 · checked 2026-11-09 15:47 UTC